Less than two months after Genzyme’s newest drug to treat multiple sclerosis was approved in Europe, U.S. regulators said in a report today that its health risk may outweigh the benefits, and ...

BERLIN — New data from two new studies suggest that for patients with multiple sclerosis (MS) for whom treatment with natalizumab (Tysabri, Biogen) or fingolimod (Gileyna, Novartis) fails, switching ...

While yesterday’s news that Genzyme planned to resubmit an application for its previously-rejected multiple sclerosis drug couldn't have come too soon for patients ...

(AP) The U.S. Food and Drug Administration has notified drug maker Genzyme that its treatment for multiple sclerosis is not ready for approval for the American market. The French pharmaceutical ...

How do you whittle 35 years of headlining business news down to a couple thousand words and a few pages? You don't. But here, we take our best shot to highlight the companies, individuals, and moments ...

Teriflunomide (Aubagio, Genzyme/Sanofi), a once-daily oral medication approved for relapsing-remitting multiple sclerosis (RRMS), significantly slows brain volume loss in these patients, a reanalysis ...